XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer

mAbs

Volumn 8, Issue 4, 2016, Pages 811-827

  Schanzer, Juergen M ^a   Wartha, Katharina ^a   Moessner, Ekkehard ^b   Hosse, Ralf J ^b   Moser, Samuel ^b   Croasdale, Rebecca ^a   Trochanowska, Halina ^b   Shao, Cuiying ^c   Wang, Peng ^c   Shi, Lei ^c   Weinzierl, Tina ^b   Rieder, Natascha ^a   Bacac, Marina ^b   Ries, Carola H ^a   Kettenberger, Hubert ^a   Schlothauer, Tilman ^a   Friess, Thomas ^a   Umana, Pablo ^b   Klein, Christian ^b  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

^b Roche Innovation Center Zurich   (Switzerland)

^c Roche Innovation Center Shanghai   (China)

Author keywords

ADCC; Bispecific antibody; EGFR; IGF 1R; Pancreatic cancer

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GANITUMAB; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G ANTIBODY XGFR; SOMATOMEDIN C; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; EGFR PROTEIN, HUMAN; SOMATOMEDIN C RECEPTOR;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; SIZE EXCLUSION CHROMATOGRAPHY; TEMPERATURE STRESS; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BIOSYNTHESIS; CELL SURVIVAL; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; DRUG SCREENING; HAMSTER; IMMUNOLOGY; PANCREAS TUMOR; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY AFFINITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; MICE; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84963588900     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1160989     Document Type: Article

References (69)

1. J.Capdevila, E.Elez, T.Macarulla, F.J.Ramos, M.Ruiz-Echarri, J.Tabernero. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev 2009; 35:354-63; PMID:19269105; http://dx.doi.org/10.1016/j.ctrv.2009.02.001
2. J.Riedemann, V.M.Macaulay. IGF1R signalling and its inhibition. Endocr Relat Cancer 2006; 13 Suppl 1:S33-43; PMID:17259557; http://dx.doi.org/10.1677/erc.1.01280
3. A.Chakravarti, J.S.Loeffler, N.J.Dyson. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62:200-7; PMID:11782378
4. H.E.Jones, L.Goddard, J.M.Gee, S.Hiscox, M.Rubini, D.Barrow, J.M.Knowlden, S.Williams, A.E.Wakeling. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004; 11:793-814; PMID:15613453; http://dx.doi.org/10.1677/erc.1.00799
5. L.Goetsch, A.Gonzalez, O.Leger, A.Beck, P.J.Pauwels, J.F.Haeuw, N.Corvaia. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 2005; 113:316-28; PMID:15386423; http://dx.doi.org/10.1002/ijc.20543
6. D.Lu, H.Zhang, H.Koo, J.Tonra, P.Balderes, M.Prewett, E.Corcoran, V.Mangalampalli, R.Bassi, D.Anselma, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; 280:19665-72; PMID:15757893; http://dx.doi.org/10.1074/jbc.M500815200
7. D.Lu, H.Zhang, D.Ludwig, A.Persaud, X.Jimenez, D.Burtrum, P.Balderes, M.Liu, P.Bohlen, L.Witte, et al. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 2004; 279:2856-65; PMID:14576153; http://dx.doi.org/10.1074/jbc.M310132200
8. P.Haluska, J.M.Carboni, C.TenEyck, R.M.Attar, X.Hou, C.Yu, M.Sagar, T.W.Wong, M.M.Gottardis, C.Erlichman. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008; 7:2589-98; PMID:18765823; http://dx.doi.org/10.1158/1535-7163.MCT-08-0493
9. V.D.Cataldo, D.L.Gibbons, R.Perez-Soler, A.Quintas-Cardama. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011; 364:947-55; PMID:21388312; http://dx.doi.org/10.1056/NEJMct0807960
10. P.A.Janne, J.C.Yang, D.W.Kim, D.Planchard, Y.Ohe, S.S.Ramalingam, M.J.Ahn, S.W.Kim, W.C.Su, L.Horn, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372:1689-99; PMID:25923549; http://dx.doi.org/10.1056/NEJMoa1411817
11. J.C.Yang, L.V.Sequist, S.L.Geater, C.M.Tsai, T.S.Mok, M.Schuler, N.Yamamoto, C.J.Yu, S.H.Ou, C.Zhou, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 2015; 16:830-8; PMID:26051236; http://dx.doi.org/10.1016/S1470-2045(15)00026-1
12. V.A.Miller, V.Hirsh, J.Cadranel, Y.M.Chen, K.Park, S.W.Kim, C.Zhou, W.C.Su, M.Wang, Y.Sun, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13:528-38; PMID:22452896; http://dx.doi.org/10.1016/S1470-2045(12)70087-6
13. B.C.Liao, C.C.Lin, J.C.Yang. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol 2015; 27:94-101; PMID:25611025; http://dx.doi.org/10.1097/CCO.0000000000000164
14. K.Politi, D.Ayeni, T.Lynch. The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic. Cancer Cell 2015; 27:751-3; PMID:26058074; http://dx.doi.org/10.1016/j.ccell.2015.05.012
15. E.Van Cutsem, C.H.Kohne, I.Lang, G.Folprecht, M.P.Nowacki, S.Cascinu, I.Shchepotin, J.Maurel, D.Cunningham, S.Tejpar, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29:2011-9; PMID:21502544; http://dx.doi.org/10.1200/JCO.2010.33.5091
16. J.B.Vermorken, R.S.Herbst, X.Leon, N.Amellal, J.Baselga. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 2008; 112:2710-9; PMID:18481809; http://dx.doi.org/10.1002/cncr.23442
17. B.Kuenen, P.O.Witteveen, R.Ruijter, G.Giaccone, A.Dontabhaktuni, F.Fox, T.Katz, H.Youssoufian, J.Zhu, E.K.Rowinsky, et al. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res 2010; 16:1915-23; PMID:20197484; http://dx.doi.org/10.1158/1078-0432.CCR-09-2425
18. N.Thatcher, F.R.Hirsch, A.V.Luft, A.Szczesna, T.E.Ciuleanu, M.Dediu, R.Ramlau, R.K.Galiulin, B.Bálint, G.Losonczy, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015; 16:763-74; PMID:26045340; http://dx.doi.org/10.1016/S1470-2045(15)00021-2
19. L.Paz-Ares, J.Mezger, T.E.Ciuleanu, J.R.Fischer, J.von Pawel, M.Provencio, A.Kazarnowicz, G.Losonczy, G.de CastroJr, A.Szczesna, L.Crino, et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol 2015; 16:328-37; PMID:25701171; http://dx.doi.org/10.1016/S1470-2045(15)70046-X
20. D.E.Oppenheim, R.Spreafico, A.Etuk, D.Malone, E.Amofah, C.Peña-Murillo, T.Murray, L.McLaughlin, B.S.Choi, S.Allan, et al. Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. Br J Cancer 2014; 110:1221-7; PMID:24496456; http://dx.doi.org/10.1038/bjc.2014.35
21. C.A.Gerdes, V.G.Nicolini, S.Herter, E.van Puijenbroek, S.Lang, M.Roemmele, E.Moessner, O.Freytag, T.Friess, C.H.Ries, et al. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res 2013; 19:1126-38; PMID:23209031; http://dx.doi.org/10.1158/1078-0432.CCR-12-0989
22. L.G.Paz-Ares, C.Gomez-Roca, J.P.Delord, A.Cervantes, B.Markman, J.Corral, J.C.Soria, Y.Bergé, D.Roda, F.Russell-Yarde, et al. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2011; 29:3783-90; PMID:21900113; http://dx.doi.org/10.1200/JCO.2011.34.8888
23. J.P.Delord, J.Tabernero, R.Garcia-Carbonero, A.Cervantes, C.Gomez-Roca, Y.Bergé, J.Capdevila, L.Paz-Ares, D.Roda, P.Delmar, et al. Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. Eur J Cancer 2014; 50:496-505; PMID:24262587; http://dx.doi.org/10.1016/j.ejca.2013.10.015
24. J.A.Bridgewater, A.Cervantes, B.Markman, et al. GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology 2015; 33:2405-6; PMID:26033821
25. R.Dienstmann, A.Patnaik, R.Garcia-Carbonero, A.Cervantes, M.Benavent, S.Roselló, B.B.Tops, R.S.van der Post, G.Argilés, N.J.Skartved, et al. Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discov 2015; 5:598-609; PMID:25962717; http://dx.doi.org/10.1158/2159-8290.CD-14-1432
26. M.W.Pedersen, H.J.Jacobsen, K.Koefoed, A.Hey, C.Pyke, J.S.Haurum, M.Kragh. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010; 70:588-97; PMID:20068188; http://dx.doi.org/10.1158/0008-5472.CAN-09-1417
27. A.S.Pappo, S.R.Patel, J.Crowley, D.K.Reinke, K.P.Kuenkele, S.P.Chawla, G.C.Toner, R.G.Maki, P.A.Meyers, R.Chugh, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011; 29:4541-7; PMID:22025149; http://dx.doi.org/10.1200/JCO.2010.34.0000
28. R.Kurzrock, A.Patnaik, J.Aisner, T.Warren, S.Leong, R.Benjamin, S.G.Eckhardt, J.E.Eid, G.Greig, K.Habben, et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 2010; 16:2458-65; PMID:20371689; http://dx.doi.org/10.1158/1078-0432.CCR-09-3220
29. C.J.Langer, S.Novello, K.Park, M.Krzakowski, D.D.Karp, T.Mok, R.J.Benner, J.R.Scranton, A.J.Olszanski, J.Jassem. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol 2014; 32:2059-66; PMID:24888810; http://dx.doi.org/10.1200/JCO.2013.54.4932
30. D.D.Karp, L.G.Paz-Ares, S.Novello, P.Haluska, L.Garland, F.Cardenal, L.J.Blakely, P.D.Eisenberg, C.J.Langer, G.BlumenscheinJr, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009; 27:2516-22; PMID:19380445; http://dx.doi.org/10.1200/JCO.2008.19.9331
31. G.V.Scagliotti, I.Bondarenko, F.Blackhall, F.Barlesi, T.C.Hsia, J.Jassem, J.Milanowski, S.Popat, J.M.Sanchez-Torres, S.Novello, et al. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Ann Oncol 2015; 26:497-504; PMID:25395283; http://dx.doi.org/10.1093/annonc/mdu517
32. B.D.Cohen, D.A.Baker, C.Soderstrom, G.Tkalcevic, A.M.Rossi, P.E.Miller, M.W.Tengowski, F.Wang, A.Gualberto, J.S.Beebe, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005; 11:2063-73; PMID:15756033; http://dx.doi.org/10.1158/1078-0432.CCR-04-1070
33. H.L.Kindler, D.A.Richards, L.E.Garbo, E.B.Garon, J.J.StephensonJr, C.M.Rocha-Lima, H.Safran, D.Chan, D.M.Kocs, F.Galimi, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 2012; 23:2834-42; PMID:22700995; http://dx.doi.org/10.1093/annonc/mds142
34. L.S.Rosen, I.Puzanov, G.Friberg, E.Chan, Y.C.Hwang, H.Deng, J.Gilbert, D.Mahalingam, I.McCaffery, S.A.Michael, et al. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin Cancer Res 2012; 18:3414-27; PMID:22510349; http://dx.doi.org/10.1158/1078-0432.CCR-11-3369
35. W.D.Tap, G.Demetri, P.Barnette, J.Desai, P.Kavan, R.Tozer, P.W.Benedetto, G.Friberg, H.Deng, I.McCaffery, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 2012; 30:1849-56; PMID:22508822; http://dx.doi.org/10.1200/JCO.2011.37.2359
36. F.Sclafani, T.Y.Kim, D.Cunningham, T.W.Kim, J.Tabernero, H.J.Schmoll, J.K.Roh, S.Y.Kim, Y.S.Park, T.K.Guren, et al. A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. J Natl Cancer Inst 2015; 107:djv258; PMID:26405092; http://dx.doi.org/10.1093/jnci/djv258
37. F.Atzori, J.Tabernero, A.Cervantes, L.Prudkin, J.Andreu, E.Rodríguez-Braun, A.Domingo, J.Guijarro, C.Gamez, J.Rodon, et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011; 17:6304-12; PMID:21810918; http://dx.doi.org/10.1158/1078-0432.CCR-10-3336
38. M.Scartozzi, M.Bianconi, E.Maccaroni, R.Giampieri, R.Berardi, S.Cascinu. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther 2010; 12:361-71; PMID:20521225
39. D.Burtrum, Z.Zhu, D.Lu, D.M.Anderson, M.Prewett, D.S.Pereira, R.Bassi, R.Abdullah, A.T.Hooper, H.Koo, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63:8912-21; PMID:14695208
40. D.L.Reidy, E.Vakiani, M.G.Fakih, M.W.Saif, J.R.Hecht, N.Goodman-Davis, E.Hollywood, J.Shia, J.Schwartz, K.Chandrawansa, et al. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol 2010; 28:4240-6; PMID:20713879; http://dx.doi.org/10.1200/JCO.2010.30.4154
41. A.Weickhardt, R.Doebele, A.Oton, J.Lettieri, D.Maxson, M.Reynolds, A.Brown, M.K.Jackson, G.Dy, A.Adjei, G.Fetterly, X.Lu, et al. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol 2012; 7:419-26; PMID:22237261; http://dx.doi.org/10.1097/JTO.0b013e31823c5b11
42. G.V.Scagliotti, S.Novello. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev 2012; 38:292-302; PMID:21907495; http://dx.doi.org/10.1016/j.ctrv.2011.07.008
43. W.T.Iams, C.M.Lovly. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade. Clin Cancer Res 2015; 21:4270-7; PMID:26429980; http://dx.doi.org/10.1158/1078-0432.CCR-14-2518
44. M.Allison. Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers. Nat Biotechnol 2012; 30:906-7; PMID:23051797; http://dx.doi.org/10.1038/nbt1012-906c
45. A.S.Pappo, G.Vassal, J.J.Crowley, V.Bolejack, P.C.Hogendoorn, R.Chugh, M.Ladanyi, J.F.Grippo, G.Dall, A.P.Staddon, et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer 2014; 120:2448-56; PMID:24797726; http://dx.doi.org/10.1002/cncr.28728
46. S.S.Ramalingam, D.R.Spigel, D.Chen, M.B.Steins, J.A.Engelman, C.P.Schneider, S.Novello, W.E.Eberhardt, L.Crino, K.Habben, et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 2011; 29:4574-80; PMID:22025157; http://dx.doi.org/10.1200/JCO.2011.36.6799
47. J.B.Fitzgerald, B.W.Johnson, J.Baum, S.Adams, S.Iadevaia, J.Tang, V.Rimkunas, L.Xu, N.Kohli, R.Rennard, et al. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther 2014; 13:410-25; PMID:24282274; http://dx.doi.org/10.1158/1535-7163.MCT-13-0255
48. C.Li, S.Huang, E.A.Armstrong, D.M.Francis, L.R.Werner, M.X.Sliwkowski, A.van der Kogel, P.M.Harari. Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers. Mol Cancer Ther 2015; 14:2049-59; PMID:26141946; http://dx.doi.org/10.1158/1535-7163.MCT-15-0155
49. S.Huang, C.Li, E.A.Armstrong, C.R.Peet, J.Saker, L.C.Amler, M.X.Sliwkowski, P.M.Harari. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 2013; 73:824-33; PMID:23172311; http://dx.doi.org/10.1158/0008-5472.CAN-12-1611
50. G.Schaefer, L.Haber, L.M.Crocker, S.Shia, L.Shao, D.Dowbenko, K.Totpal, A.Wong, C.V.Lee, S.Stawicki, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20:472-86; PMID:22014573; http://dx.doi.org/10.1016/j.ccr.2011.09.003
51. R.Castoldi, V.Ecker, L.Wiehle, M.Majety, R.Busl-Schuller, M.Asmussen, A.Nopora, U.Jucknischke, F.Osl, S.Kobold, et al. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. Oncogene 2013; 32:5593-601; PMID:23812422; http://dx.doi.org/10.1038/onc.2013.245
52. S.Zheng, S.Moores, S.Jarantow, J.Pardinas, M.Chiu, H.Zhou, W.Wang. Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody. MAbs 2016; 0:1-11; PMID:26761634; http://dx.doi.org/10.1080/19420862.2015.1136762
53. R.Castoldi, U.Jucknischke, L.P.Pradel, E.Arnold, C.Klein, S.Scheiblich, G.Niederfellner, C.Sustmann. Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. Protein Eng Des Sel 2012; 25:551-9; PMID:22936109; http://dx.doi.org/10.1093/protein/gzs048
54. S.Hu, W.Fu, W.Xu, Y.Yang, M.Cruz, S.D.Berezov, D.Jorissen, H.Takeda, W.Zhu. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Res 2015; 75:159-70; PMID:25371409; http://dx.doi.org/10.1158/0008-5472.CAN-14-1670
55. P.Umana, J.Jean-Mairet, R.Moudry, H.Amstutz, J.E.Bailey. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 1999; 17:176-80; PMID:10052355; http://dx.doi.org/10.1038/6179
56. C.Ferrara, S.Grau, C.Jager, P.Sondermann, P.Brünker, I.Waldhauer, M.Hennig, A.Ruf, A.C.Rufer, M.Stihle, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A 2011; 108:12669-74; PMID:21768335; http://dx.doi.org/10.1073/pnas.1108455108
57. J.M.Schanzer, K.Wartha, R.Croasdale, S.Moser, K.P.Künkele, C.Ries, W.Scheuer, H.Duerr, S.Pompiati, J.Pollman, et al. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties. J Biol Chem 2014; 289:18693-706; PMID:24841203; http://dx.doi.org/10.1074/jbc.M113.528109
58. J.B.Ridgway, L.G.Presta, P.Carter. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21; PMID:8844834; http://dx.doi.org/10.1093/protein/9.7.617
59. E.Buck, A.Eyzaguirre, M.Rosenfeld-Franklin, S.Thomson, M.Mulvihill, S.Barr, E.Brown, M.O'Connor, Y.Yao, J.Pachter, et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008; 68:8322-32; PMID:18922904; http://dx.doi.org/10.1158/0008-5472.CAN-07-6720
60. M.Guix, A.C.Faber, S.E.Wang, M.G.Olivares, Y.Song, S.Qu, C.Rinehart, B.Seidel, D.Yee, C.L.Arteaga, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118:2609-19; PMID:18568074
61. C.Desbois-Mouthon, A.Baron, M.J.Blivet-Van Eggelpoel, L.Fartoux, C.Venot, F.Bladt, C.Housset, O.Rosmorduc. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 2009; 15:5445-56; PMID:19706799; http://dx.doi.org/10.1158/1078-0432.CCR-08-2980
62. R.Croasdale, K.Wartha, J.M.Schanzer, K.P.Kuenkele, C.Ries, K.Mayer, C.Gassner, M.Wagner, N.Dimoudis, S.Herter, et al. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. Arch Biochem Biophys 2012; 526:206-18; PMID:22464987; http://dx.doi.org/10.1016/j.abb.2012.03.016
63. D.L.Wheeler, S.Huang, T.J.Kruser, M.M.Nechrebecki, E.A.Armstrong, S.Benavente, V.Gondi, K.T.Hsu, P.M.Harari. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008; 27:3944-56; PMID:18297114; http://dx.doi.org/10.1038/onc.2008.19
64. G.A.Lazar, W.Dang, S.Karki, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103:4005-10; PMID:16537476; http://dx.doi.org/10.1073/pnas.0508123103
65. E.Mossner, P.Brunker, S.Moser, U.Püntener, C.Schmidt, S.Herter, R.Grau, C.Gerdes, A.Nopora, E.van Puijenbroek, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393-402; PMID:20194898; http://dx.doi.org/10.1182/blood-2009-06-225979
66. V.Goede, K.Fischer, R.Busch, A.Engelke, B.Eichhorst, C.M.Wendtner, T.Chagorova, J.de la Serna, M.S.Dilhuydy, T.Illmer, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370:1101-10; PMID:24401022; http://dx.doi.org/10.1056/NEJMoa1313984
67. H.Z.Lee, B.W.Miller, V.E.Kwitkowski, S.Ricci, P.DelValle, H.Saber, J.Grillo, J.Bullock, J.Florian, N.Mehrotra, et al. U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia. Clin Cancer Res 2014; 20:3902-7; PMID:24824310
68. M.Ogura, T.Ishida, K.Hatake, M.Taniwaki, K.Ando, K.Tobinai, K.Fujimoto, K.Yamamoto, T.Miyamoto, N.Uike, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 2014; 32:1157-63; PMID:24616310; http://dx.doi.org/10.1200/JCO.2013.52.0924
69. A.Beck, J.M.Reichert. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 2012; 4:419-25; PMID:22699226; http://dx.doi.org/10.4161/mabs.20996